港股早評:恆指高開0.12%,穩定幣、創新藥繼續活躍
隔夜美股三大指數收漲,納指收漲0.25%續創收盤新高,熱門中概股多數下跌。港股三大指數漲跌不一,恆指漲0.12%,國指漲0.1%,恆生科技指數微跌0.02%。盤面上,大型科技股多數下跌,百度大跌4.46%,京東、阿里巴巴、小米走低,美團漲1%,騰訊漲0.58%;穩定幣熱潮席捲全球!穩定幣概念股集體走強,多點數智大漲超10%,國泰君安國際、中國光大控股、連連數字等多股漲超2%;創新藥概念股持續上漲,康方生物、百濟神州、金斯瑞生物科技漲幅靠前;蘋果概念股、光伏股、汽車股多數上漲。另一方面,內房股、黃金股、航空股多數走低,新城發展、綠城服務跌超1%,山東黃金、中國南方航空跌0.5%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.